Seeking new paths of innovation
News from the hub
LEO Pharma announces an investment in the biotechnology company Novopyxis to support the development of an early-stage drug delivery device designed to increase the penetration of topical treatments in the skin.
The hand-held aerosol device will be clinically tested on people with alopecia, where there is a high need for alternative treatment options to painful steroid injections. Alopecia is an autoimmune disease leading to hair loss from all or some parts of the body, usually the scalp.
Read more on LINK.
Cambridge, Mass., June 15, 2017 – LEO Science & Tech Hub today announced a two-year collaboration with the Karp Lab at Brigham and Women’s Hospital (BWH) to develop minimally-invasive technology to advance dermal biomarker assessment. The Karp Lab, led by Jeffrey Karp, PhD, at BWH focuses on the development of platform technology and translational research to improve patient care. LEO Science & Tech Hub is an R&D innovation unit of LEO Pharma dedicated to identifying, developing, and funding innovative solutions that improve the lives of people with skin diseases.
LEO Science & Tech Hub and the Karp Lab will explore and develop technologies that could enable frequent and minimally-invasive assessment of relevant dermal biomarkers during clinical studies as well as the potential for diagnostic use in point-of-care testing. This kind of assessment could limit the number of painful skin biopsies patients must endure, and provide physicians with immediate feedback on how well a drug regimen is working. Read more on the following link.
We are looking forward to host the official inauguration of the LEO Science & Tech Hub in Boston by Her Royal Highness, Crown Princess Mary of Denmark at the Cambridge Innovation Center (CIC) on Friday, September 30th, 2016. The event, which also includes participation from the Danish Minister for Business and Growth Troels Lund Poulsen, brings together members of the Boston life science community to explore opportunities for partnership and innovation.
After several months of preparation, we’re proud to announce the opening of our office at the Cambridge Innovation Center (CIC) and the launch of our website. We’re currently in the process of relocating from Denmark to the US and expect to be fully operational by July 13, 2016. If you’d like to hear more about our mission or discuss potential ways to collaborate, don’t hesitate to get in touch with us!
The team: Michael Sierra (Vice President), Georg Duenstl (Chief Scientist Pharmacology), Janni Hoejlund (Administrator, located in Denmark), Troels Marstrand (Chief Data Scientist).